Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
Larimar Therapeutics, Inc. is soliciting proxies for its 2026 virtual Annual Meeting on May 19, 2026 to vote on director elections, executive compensation advisory items, ratification of PwC as auditor, and a proposal to increase authorized common stock from 115,000,000 to 215,000,000. The record date for voting was March 25, 2026, when 103,882,937 shares of common stock were outstanding.
The Proxy Statement summarizes Board composition, governance practices, director and executive compensation, recent corporate highlights (including FDA Breakthrough Therapy designation for nomlabofusp and two 2025 underwritten offerings raising net proceeds of approximately $65.0 million and $107.6 million), audit fees and recommended votes. The Board recommends approval of all proposals, including the charter amendment to increase authorized shares.
Larimar Therapeutics is a clinical-stage biotech focused on rare diseases, led by nomlabofusp for Friedreich’s ataxia (FA). Nomlabofusp uses a cell-penetrating peptide platform to deliver frataxin into mitochondria, aiming to correct the underlying protein deficiency in FA rather than just symptoms.
The company has completed four clinical studies and is running an open-label trial with daily 50 mg dosing, where roughly 8,000 doses have been given. Nomlabofusp holds multiple U.S. and European regulatory designations, participates in FDA’s START pilot, and has Breakthrough Therapy status. Larimar targets a June 2026 BLA submission for accelerated approval using skin frataxin as a surrogate endpoint, alongside a global Phase 3 confirmatory study.
Safety is a key focus: injection site reactions are the most common adverse events, and anaphylaxis has been identified as a likely drug-related reaction, leading to protocol changes including premedication and modified initial dosing. As of December 31, 2025, cash, cash equivalents and marketable securities were $136.9 million, and a February 2026 equity offering added $107.6 million in net proceeds, which together are expected to fund operations into the second quarter of 2027.
Larimar Therapeutics reported a full-year 2025 net loss of $165.7 million, or $2.27 per common share, compared with a net loss of $80.6 million, or $1.32 per share, in 2024. Fourth quarter 2025 net loss was $62.5 million, or $0.73 per common share.
Research and development spending nearly doubled to $154.2 million in 2025, mainly from higher nomlabofusp manufacturing, clinical, and regulatory costs. The FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, and the company plans a June 2026 BLA submission with a potential U.S. launch in the first half of 2027, if approved. Cash, cash equivalents and marketable securities were $136.9 million at December 31, 2025, and pro forma liquidity of $244.5 million including the February 2026 offering is expected to fund operations into the second quarter of 2027.
Larimar Therapeutics, Inc. provides a detailed update on its nomlabofusp program for Friedreich’s ataxia, highlighting regulatory progress, clinical data and funding. Nomlabofusp holds FDA Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations, plus PRIME and other expedited designations in Europe and the UK.
The company plans a Biologics License Application seeking accelerated approval in June 2026, supported by an open-label study and a planned global Phase 3 trial using Upright Stability Score and mFARS as primary endpoints. Open-label data show sustained, dose‑dependent increases in skin frataxin, with 100% of 10 evaluated participants above 50% of healthy volunteer levels at 180 days.
Clinical outcomes over one year numerically improved across multiple measures versus a matched FACOMS natural history cohort. Around 8,000 doses have been administered; most adverse events were injection‑site reactions, though 7 of 39 open‑label participants experienced anaphylaxis that resolved with standard treatment. Pro forma cash and investments of $244.5 million as of December 31, 2025 provide an estimated runway into the second quarter of 2027.
Larimar Therapeutics’ major shareholder group Deerfield has updated its ownership following a February 2026 stock offering. Deerfield-affiliated funds bought additional common shares at $5.00 per share in an underwritten offering on February 27, 2026, using available cash.
After these purchases, Deerfield entities report beneficial ownership of 35,667,474 shares of Larimar common stock, or 34.41% of the company’s 103,590,392 shares outstanding, including those issued in the February 2026 offering. Individual Deerfield funds now hold between roughly 5.99% and 10.25% of the outstanding shares.
Larimar Therapeutics, Inc. reported that investment funds managed by Deerfield entities associated with James E. Flynn made significant open-market purchases of its common stock. On February 27, 2026, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Healthcare Innovations Fund, L.P., and Deerfield Partners, L.P. collectively bought 5,000,000 shares of Larimar common stock at $5.00 per share in indirect transactions. Following these purchases, each fund reported updated indirect holdings in Larimar, while the reporting persons collectively disclaimed beneficial ownership beyond any indirect pecuniary interest described in the footnotes.
Larimar Therapeutics, Inc. director Thomas Edward Hamilton bought 100,000 shares of common stock in an underwritten offering at $5.00 per share, which closed on February 27, 2026. Following this open-market purchase, he directly owns 664,798 shares and indirectly holds 159,433 shares through Post Edison, LLC.
Larimar Therapeutics director Frank E. Thomas bought common stock in the company through its underwritten offering. On February 27, 2026, he purchased 5,000 shares of Larimar Therapeutics common stock at $5.00 per share in an open-market style purchase tied to the offering. After this transaction, he directly owned 7,000 shares of common stock.
Larimar Therapeutics director Jeffrey W. Sherman bought 5,000 shares of the company’s common stock at $5.00 per share in an underwritten offering that closed on February 27, 2026. The transaction is reported as a direct, open-market style purchase on a Form 4 insider filing.
Larimar Therapeutics, Inc. entered into an underwriting agreement to sell 20,000,000 shares of common stock at a public offering price of $5.00 per share. The underwriters also received a 30-day option to buy up to 3,000,000 additional shares, which was fully exercised on February 26, 2026.
After underwriting discounts, commissions and estimated expenses, the Company expects net proceeds of approximately $107.6 million from this offering. All shares are being sold by the Company under an existing Form S-3 shelf registration, and the offering is expected to close on February 27, 2026, subject to customary closing conditions.